Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityNo recent work listed

Xing Liang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4406-0753; OpenAlex author ID A5101459979. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers

Papers 9

  1. Identifying Liver Metastasis-Related Genes Through a Coexpression Network to Construct a 5-Gene Model for Predicting Pancreatic Ductal Adenocarcinoma Patient P… Co-author DOI 10.1097/mpa.0000000000002229↗
  2. PLAGL1 is associated with prognosis and cell proliferation in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12876-022-02609-y↗
  3. Development of a Gene Risk Signature for Patients of Pancreatic Cancer. Co-author DOI 10.1155/2022/4136825↗
  4. The RNA methyltransferase NSUN6 suppresses pancreatic cancer development by regulating cell proliferation. First author DOI 10.1016/j.ebiom.2020.103195↗
  5. SYT8 promotes pancreatic cancer progression via the TNNI2/ERRα/SIRT1 signaling pathway. First author DOI 10.1038/s41420-021-00779-4↗
  6. Identification of novel hub genes and lncRNAs related to the prognosis and progression of pancreatic cancer by microarray and integrated bioinformatics analysi… Co-author DOI 10.21037/gs-21-151↗
  7. Downregulated F-Box/LRR-Repeat Protein 7 Facilitates Pancreatic Cancer Metastasis by Regulating Snail1 for Proteasomal Degradation. Co-author DOI 10.3389/fgene.2021.650090↗
  8. Network-based integration of mRNA and miRNA profiles reveals new target genes involved in pancreatic cancer. Co-author DOI 10.1002/mc.22920↗
  9. Long non-coding RNA CUDR promotes malignant phenotypes in pancreatic ductal adenocarcinoma via activating AKT and ERK signaling pathways. Co-author DOI 10.3892/ijo.2018.4574↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chenghao Shao · 8 shared papers, 2018–2023 · strength 1.10
  2. Zhiping Fu · 4 shared papers, 2021–2023 · strength 0.59
  3. An‐An Liu · 3 shared papers, 2018–2023 · strength 0.40
  4. Ju‐Dong Li · 2 shared papers, 2022–2023 · strength 0.33
  5. Anan Liu · 2 shared papers, 2021–2023 · strength 0.31
  6. Linhua Yang · 2 shared papers, 2021–2023 · strength 0.31
  7. Liang V. Tang · 2 shared papers, 2021 · strength 0.27
  8. Tao Liu · 1 shared paper, 2023 · strength 0.18
  9. Xiaoqiang Dong · 1 shared paper, 2023 · strength 0.18
  10. Lixing Zhan · 2 shared papers, 2018–2019 · strength 0.17
  11. Long Chen · 1 shared paper, 2022 · strength 0.16
  12. Tao Liu · 1 shared paper, 2022 · strength 0.16
  13. Ming Zhan · 1 shared paper, 2021 · strength 0.13
  14. Yongwei Sun · 1 shared paper, 2021 · strength 0.13
  15. Ruimeng Yang · 1 shared paper, 2021 · strength 0.13
  16. Jie Lin · 1 shared paper, 2019 · strength 0.09
  17. Yan Zhang · 1 shared paper, 2019 · strength 0.09
  18. Xiangui Hu · 1 shared paper, 2018 · strength 0.08
  19. Jun Chen · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.